Publicerat: 2020-08-01 13:14:58

Ritzau om Scandion Oncology: Scandion Oncology announces that one of its founders, Saniona, has reduced its shareholding to below 10% of the total share amount

For further information regarding Scandion Oncology, please contact: Nils Brünner, CEO Phone: +45 26 14 47 08 E-mail: nb@scandiononcology.com This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on August 1, 2020. Scandion Oncology A/S is a biotechnology company that addresses and targets one of the greatest challenges in modern oncology - the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro studies, SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company's leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. For further information, please see: www.scandiononcology.com.Scandion Oncology A/S

Läs mer om Scandion Oncology